Skip to content

ADMA Biologics ADMA Issuance of warrants to purchase common stock

Issuance of warrants to purchase common stock at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.52M-75.7%
NovaGold Resources logo
NovaGold ResourcesNG
$9.9M
KEE
Keel Infrastructure Corp. Common StockKEEL
$11.48M
ADMA Biologics logo
ADMA BiologicsADMA
$1.4M
ADMA Biologics logo
ADMA BiologicsADMA
$1.4M
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$2.52M-75.7%

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.

The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's issuance of warrants to purchase common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's issuance of warrants to purchase common stock?
ADMA Biologics (ADMA) reported issuance of warrants to purchase common stock of $1.4M in Q4 2023.
What does issuance of warrants to purchase common stock mean?
This reflects the accounting value assigned to warrants issued to purchase common stock, typically as part of financing arrangements or incentive packages. It measures the potential future dilution and the capital structure impact of derivative equity instruments.